Search
Repaglinide
go.drugbank.com/drugs/DB00912ApprovedInvestigationalThe average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.
Alpha-1-proteinase inhibitor
go.drugbank.com/drugs/DB00058ApprovedInvestigationalHuman alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
Sarafloxacin
go.drugbank.com/drugs/DB11491ApprovedVet approvedWithdrawnSarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Riluzole
go.drugbank.com/drugs/DB00740ApprovedInvestigationalRiluzole is marketed as Rilutek by Sanofi.
Pazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalIt is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Bethanechol
go.drugbank.com/drugs/DB01019ApprovedAn advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]
Mephentermine
go.drugbank.com/drugs/DB01365ApprovedWithdrawnA sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine ...
Flurbiprofen
go.drugbank.com/drugs/DB00712ApprovedInvestigationalFlurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, os...
Econazole
go.drugbank.com/drugs/DB01127ApprovedA broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Patisiran
go.drugbank.com/drugs/DB14582ApprovedPatisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].